Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Current Assets of $602.8 million for Q2 2026, down 0.66% year-over-year from $606.8 million in Q2 2025, and down 3.71% quarter-over-quarter from $626.0 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Current Assets for 17 consecutive years, with $602.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets fell 0.66% year-over-year to $602.8 million; the TTM figure through Jun 2026 stood at $602.8 million (down 0.66% YoY), while the FY2025 annual figure was $649.9 million, up 9.15% from the prior year.
- Current Assets eased to $602.8 million in Q2 2026 per AMRN's latest filing, from $626.0 million in the prior quarter.
- Across five years, Current Assets topped out at $772.6 million in Q1 2022 and bottomed at $573.1 million in Q1 2025.
- Historically, Current Assets has averaged $667.9 million across 5 years, with a median of $685.2 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets fell 28.71% — and 2026, when it gained 9.23%.
- Amarin Corp Plc\Uk's Current Assets stood at $689.1 million in 2022, then rose by 5.21% to $725.0 million in 2023, then fell by 17.87% to $595.4 million in 2024, then increased by 9.15% to $649.9 million in 2025, then decreased by 7.24% to $602.8 million in 2026.
- Business Quant data shows AMRN's Current Assets at $602.8 million in Q2 2026, $626.0 million in Q1 2026, and $649.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 602.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 602.80 Mn |
| Mar 31, 2026 | 626.02 Mn |
| Dec 31, 2025 | 649.88 Mn |
| Sep 30, 2025 | 628.33 Mn |
| Jun 30, 2025 | 606.82 Mn |
| Mar 31, 2025 | 573.10 Mn |
| Dec 31, 2024 | 595.40 Mn |
| Sep 30, 2024 | 650.22 Mn |
| Jun 30, 2024 | 701.84 Mn |
| Mar 31, 2024 | 687.93 Mn |
| Dec 31, 2023 | 724.98 Mn |
| Sep 30, 2023 | 717.51 Mn |
| Jun 30, 2023 | 706.50 Mn |
| Mar 31, 2023 | 683.82 Mn |
| Dec 31, 2022 | 689.10 Mn |
| Sep 30, 2022 | 686.52 Mn |
| Jun 30, 2022 | 719.12 Mn |
| Mar 31, 2022 | 772.62 Mn |
| Dec 31, 2021 | 878.73 Mn |
| Sep 30, 2021 | 963.03 Mn |